|1.||Toral-Barza, Lourdes: 3 articles (01/2012 - 01/2010)|
|2.||Yu, Ker: 3 articles (01/2012 - 01/2010)|
|3.||Shor, Boris: 2 articles (05/2010 - 01/2010)|
|4.||Shi, Celine: 2 articles (05/2010 - 01/2010)|
|5.||Follettie, Max: 1 article (05/2010)|
|6.||Wu, Jiang: 1 article (05/2010)|
|7.||Shakey, Quazi: 1 article (05/2010)|
|8.||Gibbons, James J: 1 article (01/2010)|
|9.||Curran, Kevin: 1 article (01/2010)|
|10.||Verheijen, Jeroen: 1 article (01/2010)|
01/15/2010 - "Importantly, consistent with genetic ablation of mTORC2, WYE-132 targeted P-AKT(S473) and AKT function without significantly reducing the steady-state level of the PI3K/PDK1 activity biomarker P-AKT(T308), highlighting a prominent and direct regulation of AKT by mTORC2 in cancer cells. "
01/15/2010 - "WYE-132 inhibited mTORC1 and mTORC2 in diverse cancer models in vitro and in vivo. "
01/01/2012 - "As mTORC1 and mTORC2 mediate diverse sets of both redundant and distinctive cellular pathways of growth, nutrient and energy homeostasis, rapamycin and WYE-125132 elicit both overlapping and distinctive pharmacological properties with important implications in treating cancer, metabolic, and age-related degenerative diseases. "
01/15/2010 - "Our results further validate mTOR as a critical driver for tumor growth, establish WYE-132 as a potent and profound anticancer agent, and provide a strong rationale for clinical development of specific mTOR kinase inhibitors as new cancer therapy."
01/15/2010 - "An optimal dose of WYE-132 achieved a substantial regression of MDA361 and A549 large tumors and caused complete regression of A498 large tumors when coadministered with bevacizumab. "
|3.||Breast Neoplasms (Breast Cancer)
01/01/2012 - "Detailed methods are described for the determination of mTOR inhibition by rapamycin and WYE-125132 in assays of recombinant mTOR enzyme, immunprecipitated native mTOR complexes, growth factor- and amino acid-induced cellular phosphorylation cascades as well as the PI3K/AKT/mTOR hyperactive breast tumor model in vitro and in vivo. "